Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1

References

• Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39. doi:10.1189/jlb.1212621.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172.
   PubMed Web of Science ®Google Scholar
• Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discovery. 2013;12(2):130–146. doi:10.1038/nrd3877.
   PubMed Web of Science ®Google Scholar
• June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, Grupp SA, Porter DL. Engineered T cells for cancer therapy. Cancer Immunol, ImmunoTher. 2014;63(9):969–975. doi:10.1007/s00262-014-1568-1.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25(1):267–296. doi:10.1146/annurev.immunol.25.022106.141609.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Slaney CY, Darcy PK. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunol. 2014;3(5):e16. doi:10.1038/cti.2014.7.
   PubMedGoogle Scholar
• Svane IM, Verdegaal EM. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Cancer Immunol, ImmunoTher. 2014;63(10):1081–1091. doi:10.1007/s00262-014-1580-5.
   PubMed Web of Science ®Google Scholar
• Grakoui A. The immunological synapse: a molecular machine controlling T cell activation. Science. 1999;285(5425):221–227. doi:10.1126/science.285.5425.221.
   PubMed Web of Science ®Google Scholar
• Davis DM, Chiu I, Fassett M, Cohen GB, Mandelboim O, Strominger JL. The human natural killer cell immune synapse. Proc Natl Acad Sci USA. 1999;96(26):15062–15067. doi:10.1073/pnas.96.26.15062.
   PubMed Web of Science ®Google Scholar
• Meuer SC, Hussey RE, Fabbi M, Fox D, Acuto O, Fitzgerald KA, Hodgdon JC, Protentis JP, Schlossman SF, Reinherz EL. An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell. 1984;36(4):897–906. doi:10.1016/0092-8674(84)90039-4.
   PubMed Web of Science ®Google Scholar
• Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995;3(1):87–98. doi:10.1016/1074-7613(95)90161-2.
   PubMed Web of Science ®Google Scholar
• Radvanyi LG, Shi Y, Vaziri H, Sharma A, Dhala R, Mills GB, Miller RG. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol. 1996;156(5):1788–1798.
   PubMed Web of Science ®Google Scholar
• Samstag Y, Eibert SM, Klemke M, Wabnitz GH. Actin cytoskeletal dynamics in T lymphocyte activation and migration. J Leukoc Biol. 2003;73(1):30–48. doi:10.1189/jlb.0602272.http.
   PubMed Web of Science ®Google Scholar
• van Kooyk Y, van Vliet SJ, Figdor CGC. The actin cytoskeleton regulates LFA-1 ligand binding through avidity rather than affinity changes. J Biol Chem. 1999;274(38):26869–26877. doi:10.1074/jbc.274.38.26869.
   PubMed Web of Science ®Google Scholar
• Lees-Miller JP, Heeley DH, Smillie LB, Kay CM. Isolation and characterization of an abundant and novel 22-kDa protein (SM22) from chicken gizzard smooth muscle. J Biol Chem. 1987;262(7):2988–2993.
   PubMed Web of Science ®Google Scholar
• Shapland C, Hsuan JJ, Totty NF, Lawson D. Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J Cell Biol. 1993;121(5):1065–1073. doi:10.1083/jcb.121.5.1065.
   PubMed Web of Science ®Google Scholar
• Na B-R, Kim H-R, Piragyte I, Oh H-M, Kwon M-S, Akber U, Lee H-S, Park D-S, Song WK, Park Z-Y, et al. TAGLN2 regulates T cell activation by stabilizing the actin cytoskeleton at the immunological synapse. J Cell Biol. 2015;209(1):143–162. doi:10.1083/jcb.201407130.
   PubMed Web of Science ®Google Scholar
• Katagiri K, Hattori M, Minato N, Kinashi T. Rap1 functions as a key regulator of T-cell and antigen-presenting cell interactions and modulates T-cell responses. Mol Cell Biol. 2002;22(4):1001–1015. doi:10.1128/MCB.22.4.1001.
   PubMed Web of Science ®Google Scholar
• Katagiri K, Maeda A, Shimonaka M, Kinashi T. RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1. Nat Immunol. 2003;4(8):741–748. doi:10.1038/ni950.
   PubMed Web of Science ®Google Scholar
• Sebzda E, Bracke M, Tugal T, Hogg N, Cantrell DA. Rap1A positively regulates T cells via integrin activation rather than inhibiting lymphocyte signaling. Nat Immunol. 2002;3(3):251–258. doi:10.1038/ni765.
   PubMed Web of Science ®Google Scholar
• Kamimura K, Suda T, Zhang G, Liu D. Advances in gene delivery systems. Pharmaceut Med. 2011;25(5):293–306. doi:10.1007/BF03256872.
   PubMedGoogle Scholar
• van den Berg A, Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules. Curr Opin Biotechnol. 2011;22(6):888–893. doi:10.1016/j.copbio.2011.03.008.
   PubMed Web of Science ®Google Scholar
• Pandit S, Zhou Y, Shiue L, Coutinho-Mansfield G, Li H, Qiu J, Huang J, Yeo GW, Ares M, Fu XD. Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol Cell. 2013;50(2):223–235. doi:10.1016/j.molcel.2013.03.001.
   PubMed Web of Science ®Google Scholar
• Piragyte I, Jun C-D. Actin engine in immunological synapse. Immune Netw. 2012;12(3):71–83. doi:10.4110/in.2012.12.3.71.
   PubMedGoogle Scholar
• Ritter AT, Angus KL, Griffiths GM. The role of the cytoskeleton at the immunological synapse. Immunol Rev. 2013;256(1):107–117. doi:10.1111/imr.12117.
   PubMed Web of Science ®Google Scholar
• Kim H-R, Lee H-S, Lee K-S, Jung ID, Kwon M-S, Kim C-H, Kim S-M, Yoon M-H, Park Y-M, Lee S-M, et al. An essential role for TAGLN2 in phagocytosis of lipopolysaccharide-activated macrophages. Sci Rep. 2017;7(1):8731. doi:10.1038/s41598-017-09144-x.
   PubMedGoogle Scholar
• Wang C, Morley SC, Donermeyer D, Peng I, Lee WP, Devoss J, Danilenko DM, Lin Z, Zhang J, Zhou J, et al. Actin-bundling protein L-plastin regulates T cell activation. J Immunol. 2010;185(12):7487–7497. doi:10.4049/jimmunol.1001424.
   PubMed Web of Science ®Google Scholar
• Eibert SM, Lee K-H, Pipkorn R, Sester U, Wabnitz GH, Giese T, Meuer SC, Samstag Y. Cofilin peptide homologs interfere with immunological synapse formation and T cell activation. Proc Natl Acad Sci USA. 2004;101(7):1957–1962. doi:10.1073/pnas.0308282100.
   PubMed Web of Science ®Google Scholar
• Gimona M, Mital R. The single CH domain of calponin is neither sufficient nor necessary for F-actin binding. J Cell Sci. 1998;111(13):1813–1821.
   PubMedGoogle Scholar
• Comrie WA, Burkhardt JK. Action and traction: cytoskeletal control of receptor triggering at the immunological synapse. Front Immunol. 2016;7:(MAR):1–25. doi:10.3389/fimmu.2016.00068.
   PubMed Web of Science ®Google Scholar
• Reina M, Espel E. Role of LFA-1 and ICAM-1 in cancer. Cancers. 2017;9(12):1–14. doi:10.3390/cancers9110153.
   Google Scholar
• Mukai S, Kagamu H, Shu S, Plautz GE. Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells. Cell Immunol. 1999;192:122–132. doi:10.1006/cimm.1998.1439.
   PubMed Web of Science ®Google Scholar
• Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature. 1989;341(6243):619–624. doi:10.1038/341619a0.
   PubMed Web of Science ®Google Scholar
• Kandula S, Abraham C. LFA-1 on CD4+ T cells is required for optimal antigen-dependent activation in vivo. J Immunol. 2004;173(7):4443–4451. doi:10.4049/jimmunol.173.7.4443.
   PubMed Web of Science ®Google Scholar
• Park EJ, Peixoto A, Imai Y, Goodarzi A, Cheng G, Carman CV, Von Andrian UH, Shimaoka M. Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes. Blood. 2010;115(8):1572–1581. doi:10.1182/blood-2009-08-237917.
   PubMed Web of Science ®Google Scholar
• Dippold W, Wittig B, Schwaeble W, Mayet W, Meyer zum Buschenfelde KH. Expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in colonic epithelial cells. Gut. 1993;34(11):1593–1597. doi:10.1136/gut.34.11.1593.
   PubMed Web of Science ®Google Scholar
• Wimmenauer S, Keller H, Ruckauer KD, Rahner S, Wolff-Vorbeck G, Kirste G, von Kleist S, Farthman EH. Expression of CD44, ICAM-1 and N-CAM in colorectal cancer. Correlation with the tumor stage and the phenotypical characteristics of tumor- infiltrating lymphocytes. Anticancer Res. 1997;17(4A):2395–2400.
   PubMed Web of Science ®Google Scholar
• Lu W, Dong Z, Donawho C, Fidler IJ. ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer. 2002;100(4):486–490. doi:10.1002/ijc.10514.
   PubMed Web of Science ®Google Scholar
• Tachimori A, Yamada N, Sakate Y, Yashiro M, Maeda K, Ohira M, Nishino H, Hirakawa K. Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma. Eur J Cancer. 2005;41(12):1802–1810. doi:10.1016/j.ejca.2005.04.036.
   PubMed Web of Science ®Google Scholar
• Basingab FS, Ahmadi M, Morgan DJ. IFNγ-dependent interactions between ICAM-1 and LFA-1 counteract prostaglandin E2-mediated inhibition of antitumor CTL responses. Cancer Immunol Res. 2016;4(5):400–411. doi:10.1158/2326-6066.CIR-15-0146.
   PubMed Web of Science ®Google Scholar
• Schröder C, Witzel I, Müller V, Krenkel S, Wirtz RM, Jänicke F, Schumacher U, Milde-Langosch K. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol. 2011;137(8):1193–1201. doi:10.1007/s00432-011-0984-2.
   PubMed Web of Science ®Google Scholar
• Dezfouli S, Hatzinisiriou I, Ralph SJ. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNγ primed and IFNβ treated B7-1 + B16-F10 melanoma cells. Immunol Cell Biol. 2003;81(6):459–471. doi:10.1046/j.0818-9641.2003.01189.x.
   PubMed Web of Science ®Google Scholar
• Harada H, Kizaka-Kondoh S, Hiraoka M. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer. 2006;13(1):16–26. doi:10.2325/jbcs.13.16.
   PubMedGoogle Scholar
• Eggermont LJ, Paulis LE, Tel J, Figdor CG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 2014;32(9):456–465. doi:10.1016/j.tibtech.2014.06.007.
   PubMed Web of Science ®Google Scholar